EVO756

Overview

• Priority class: MRGPRX2
• Mechanistic bucket: MRGPRX2-pathway program
• Sponsor: Evommune
• Development focus: Active clinical development represented in current raw-source layer
• Indications represented in current raw sources: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

Strategy readout

• Headline: Parallel MRGPRX2 development in CSU and CIndU from the phase 2 stage.
• Current strategic read: The current raw-source layer suggests Evommune is not waiting to prove one urticaria subtype first. Instead, EVO756 is being positioned as a broader urticaria mechanism program with concurrent phase 2 activity in CSU and CIndU.
• Highest visible phase in current registry: Phase 2
• Strategy confidence in current local layer: Medium

Why this looks like the strategy

• Visible trials cover both CIndU and CSU rather than a single lead indication.
• The phase 2b CSU study plus separate CIndU study suggest deliberate dual-path development early in the program.

What to watch next

• Which subtype becomes the commercial or registrational lead as more efficacy detail becomes source-backed.

Operational study design view

Study Inventory

Completed / historical studies

• NCT06603220 - Phase 2; COMPLETED; Chronic Inducible Urticaria

Active / recruiting studies

• NCT06873516 - Phase 2; RECRUITING; Chronic Spontaneous Urticaria

Other registry entries

• None in current registry

Program Results Summary

Trials with source-backed results in the current local layer: 1 of 2

NCT06603220 (Conference) - Open-label study in symptomatic dermographism (n = 30, 300 mg QD or 50 mg BID, 4 weeks). - No serious TEAEs; no discontinuations due to AEs; well tolerated and consistent with Phase 1 profile. - Sources: raw/sponsors/mrgprx2/evo756/eadv-2025-cindu-presentation-pdf.md; raw/sponsors/mrgprx2/evo756/cindu-top-line-press-release-pdf.md

Sponsor-sourced result evidence

Phase 1 proof-of-concept data available from GA2LEN 2024 presentation (sponsor-sourced), in addition to Phase 2 CIndU trial results.

EVO756 Phase 1 SAD/MAD proof-of-concept in healthy volunteers (Conference (sponsor presentation)) - Proof-of-concept trial in 132 subjects showed robust target engagement via icatibant skin challenge. - EVO756 significantly inhibited wheal formation induced by icatibant at multiple dose levels after 14 days of treatment. - PK profile supports once-daily oral dosing. - Safety: Well tolerated; TEAE rate comparable with placebo across all dosing cohorts. - Safety: No severe or serious adverse events; most common TEAEs: headache and IV catheter site pain. - Source(s): raw/sponsors/mrgprx2/evo756/ga2len-2024-trial-results-presentation-pdf.md

Evidence Coverage

• CT.gov trials in registry: 2
• Sponsor artifacts in registry: 7
• Primary publications in registry: 0
• Supporting publications in registry: 0
• Publication status: no_pubmed_hits
• Publication summary: No PubMed hits were returned for EVO756 AND urticaria in this pass.

Primary publications

• No primary publications currently linked in the registry

Supporting evidence

• No supporting publications currently listed
• Sponsor artifact: MRGPRX2 antagonist program page (Evommune)
• raw/sponsors/mrgprx2/evo756/mrgprx2-antagonist-program-page.html
• raw/sponsors/mrgprx2/evo756/mrgprx2-antagonist-program-page.md
• Sponsor artifact: Clinical trials page (Evommune)
• raw/sponsors/mrgprx2/evo756/clinical-trials-page.html
• raw/sponsors/mrgprx2/evo756/clinical-trials-page.md
• Sponsor artifact: CIndU Phase 2 trial initiation PDF (Evommune)
• raw/sponsors/mrgprx2/evo756/cindu-phase-2-trial-initiation-pdf.pdf
• raw/sponsors/mrgprx2/evo756/cindu-phase-2-trial-initiation-pdf.txt
• raw/sponsors/mrgprx2/evo756/cindu-phase-2-trial-initiation-pdf.md
• Sponsor artifact: GA2LEN 2024 trial results presentation PDF (Evommune)
• raw/sponsors/mrgprx2/evo756/ga2len-2024-trial-results-presentation-pdf.pdf
• raw/sponsors/mrgprx2/evo756/ga2len-2024-trial-results-presentation-pdf.txt
• raw/sponsors/mrgprx2/evo756/ga2len-2024-trial-results-presentation-pdf.md
• Sponsor artifact: CSU Phase 2b trial initiation PDF (Evommune)
• raw/sponsors/mrgprx2/evo756/csu-phase-2b-trial-initiation-pdf.pdf
• raw/sponsors/mrgprx2/evo756/csu-phase-2b-trial-initiation-pdf.txt
• raw/sponsors/mrgprx2/evo756/csu-phase-2b-trial-initiation-pdf.md
• Sponsor artifact: CIndU top-line press release PDF (Evommune)
• raw/sponsors/mrgprx2/evo756/cindu-top-line-press-release-pdf.pdf
• raw/sponsors/mrgprx2/evo756/cindu-top-line-press-release-pdf.txt
• raw/sponsors/mrgprx2/evo756/cindu-top-line-press-release-pdf.md
• Sponsor artifact: EADV 2025 CIndU presentation PDF (Evommune)
• raw/sponsors/mrgprx2/evo756/eadv-2025-cindu-presentation-pdf.pdf
• raw/sponsors/mrgprx2/evo756/eadv-2025-cindu-presentation-pdf.txt
• raw/sponsors/mrgprx2/evo756/eadv-2025-cindu-presentation-pdf.md

Interpretation

• Verified facts: the current v2 registry tracks 2 CT.gov entries for this program and links them conservatively to sponsor and publication evidence where explicit identifiers are available.
• Interpretation: this program is currently supported mainly by CT.gov and/or sponsor-source evidence, with weaker direct manuscript coverage in the local cache.
• Open questions:
• Several sponsor artifacts remain program-level because no explicit study identifier was captured in cached metadata.

Provenance

• Primary source(s):
• ../inventories/source_registry.json
• ../inventories/source_registry.md
• Supporting source(s):
• ../inventories/ctgov_priority_trials.json
• ../inventories/publication_priority_curation.json
• ../inventories/sponsor_priority_sources.json
• Last verified: 2026-04-08
• Verification status: Partial

Change Log

• 2026-04-08: Generated or refreshed this program page from the v2 source registry and local source caches.